» Articles » PMID: 37339777

Maximin Optimal Cluster Randomized Designs for Assessing Treatment Effect Heterogeneity

Overview
Journal Stat Med
Publisher Wiley
Specialty Public Health
Date 2023 Jun 20
PMID 37339777
Authors
Affiliations
Soon will be listed here.
Abstract

Cluster randomized trials (CRTs) are studies where treatment is randomized at the cluster level but outcomes are typically collected at the individual level. When CRTs are employed in pragmatic settings, baseline population characteristics may moderate treatment effects, leading to what is known as heterogeneous treatment effects (HTEs). Pre-specified, hypothesis-driven HTE analyses in CRTs can enable an understanding of how interventions may impact subpopulation outcomes. While closed-form sample size formulas have recently been proposed, assuming known intracluster correlation coefficients (ICCs) for both the covariate and outcome, guidance on optimal cluster randomized designs to ensure maximum power with pre-specified HTE analyses has not yet been developed. We derive new design formulas to determine the cluster size and number of clusters to achieve the locally optimal design (LOD) that minimizes variance for estimating the HTE parameter given a budget constraint. Given the LODs are based on covariate and outcome-ICC values that are usually unknown, we further develop the maximin design for assessing HTE, identifying the combination of design resources that maximize the relative efficiency of the HTE analysis in the worst case scenario. In addition, given the analysis of the average treatment effect is often of primary interest, we also establish optimal designs to accommodate multiple objectives by combining considerations for studying both the average and heterogeneous treatment effects. We illustrate our methods using the context of the Kerala Diabetes Prevention Program CRT, and provide an R Shiny app to facilitate calculation of optimal designs under a wide range of design parameters.

Citing Articles

Estimates of intra-cluster correlation coefficients from 2018 USA Medicare data to inform the design of cluster randomized trials in Alzheimer's and related dementias.

Ouyang Y, Li F, Li X, Bynum J, Mor V, Taljaard M Trials. 2024; 25(1):732.

PMID: 39478608 PMC: 11523597. DOI: 10.1186/s13063-024-08404-2.


Sample size and power calculation for testing treatment effect heterogeneity in cluster randomized crossover designs.

Wang X, Chen X, Goldfeld K, Taljaard M, Li F Stat Methods Med Res. 2024; 33(7):1115-1136.

PMID: 38689556 PMC: 11347095. DOI: 10.1177/09622802241247736.


Assessing treatment effect heterogeneity in the presence of missing effect modifier data in cluster-randomized trials.

Blette B, Halpern S, Li F, Harhay M Stat Methods Med Res. 2024; 33(5):909-927.

PMID: 38567439 PMC: 11041086. DOI: 10.1177/09622802241242323.

References
1.
Brookes S, Whitely E, Egger M, Davey Smith G, Mulheran P, Peters T . Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol. 2004; 57(3):229-36. DOI: 10.1016/j.jclinepi.2003.08.009. View

2.
Korevaar E, Kasza J, Taljaard M, Hemming K, Haines T, Turner E . Intra-cluster correlations from the CLustered OUtcome Dataset bank to inform the design of longitudinal cluster trials. Clin Trials. 2021; 18(5):529-540. DOI: 10.1177/17407745211020852. View

3.
van Breukelen G, Candel M, Berger M . Relative efficiency of unequal versus equal cluster sizes in cluster randomized and multicentre trials. Stat Med. 2006; 26(13):2589-603. DOI: 10.1002/sim.2740. View

4.
Zou G, Donner A . Confidence interval estimation of the intraclass correlation coefficient for binary outcome data. Biometrics. 2004; 60(3):807-11. DOI: 10.1111/j.0006-341X.2004.00232.x. View

5.
Campbell M, Piaggio G, Elbourne D, Altman D . Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012; 345:e5661. DOI: 10.1136/bmj.e5661. View